54 episodes

PeerView (PVI) is a leading provider of high-quality, innovative continuing education (CME/CE/CPE and MOC) for clinicians and their interprofessional teams. Combining evidence-based medicine and instructional expertise, PeerView activities improve the knowledge, skills, and strategies that support clinical performance and patient outcomes. PeerView makes its educational programming and expert-led presentations and symposia available through its network of popular podcast channels to support specific specialties and conditions. Each episode includes a link to request CME/CE credit for participation. PeerView is solely responsible for the selection of topics, the preparation of editorial content, and the distribution of all materials it publishes.

PeerView Endocrinology & Diabetes CME/CNE/CPE Audio Podcast PVI, PeerView Institute for Medical Education

    • Science
    • 3.3 • 4 Ratings

PeerView (PVI) is a leading provider of high-quality, innovative continuing education (CME/CE/CPE and MOC) for clinicians and their interprofessional teams. Combining evidence-based medicine and instructional expertise, PeerView activities improve the knowledge, skills, and strategies that support clinical performance and patient outcomes. PeerView makes its educational programming and expert-led presentations and symposia available through its network of popular podcast channels to support specific specialties and conditions. Each episode includes a link to request CME/CE credit for participation. PeerView is solely responsible for the selection of topics, the preparation of editorial content, and the distribution of all materials it publishes.

    Rajiv Agarwal, MD, MS - A Renewed Look at MRA Therapy: Improving Renal Outcomes and Reducing Risks in Patients With Type 2 Diabetes

    Rajiv Agarwal, MD, MS - A Renewed Look at MRA Therapy: Improving Renal Outcomes and Reducing Risks in Patients With Type 2 Diabetes

    Go online to PeerView.com/JNH860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert nephrologist examines the pathophysiology of chronic kidney disease (CKD) and the effects of mineralocorticoid receptor overactivation in patients with type 2 diabetes (T2D) to offer practical strategies for identifying which patients with CKD and T2D may benefit from treatment with nonsteroidal MRAs. Upon completion of this activity, participants should be better able to: Explain the pathophysiology of CKD progression and the effects of mineralocorticoid receptor overactivation in patients with T2D, Compare the mechanism of action, potency, selectivity, and physiological distribution of steroidal and nonsteroidal MRAs, Identify patients with CKD and T2D that may derive specific benefit from treatment with nonsteroidal MRAs.

    • 36 min
    Lucia M. Novak, MSN, ANP-BC, BC-ADM - Building Skills for Clinical Practice: Optimizing Insulin Management and Personalizing Diabetes Care With Faster-Acting Formulations and Newer Options in Delivery Technology

    Lucia M. Novak, MSN, ANP-BC, BC-ADM - Building Skills for Clinical Practice: Optimizing Insulin Management and Personalizing Diabetes Care With Faster-Acting Formulations and Newer Options in Delivery Technology

    Go online to PeerView.com/TZT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Insulin is often a necessary treatment for people with diabetes. Yet, knowing when to properly initiate and titrate insulin therapy in people with type 1 and type 2 diabetes is unfamiliar to many clinicians. In this activity, an expert discusses current guidance for incorporating individual preferences in insulin therapy in a variety of treatment regimens, models effective communication strategies in telehealth visits, and offers approaches to overcome common barriers to therapeutic inertia and engage patients to improve time in range and reduce postprandial glucose excursions. Upon completion of this activity, participants should be better able to: Incorporate newer options in mealtime insulin and the latest advances in technology to overcome barriers to insulin initiation, simplify insulin delivery and dosing, improve postprandial glucose (PPG) levels and time in range (TIR), and enhance the quality of life in patients with insulin-treated diabetes, Engage in patient-centered discussions across the interprofessional care team to optimize use of the latest advances in rapid acting insulin and insulin technology to support patient-centered diabetes care.

    • 57 min
    Javier Morales, MD, FACP, FACE - Is Synergism the Secret to Success? Candid Conversations on Targeting GIP and GLP-1 to Individualize Treatment in Patients With T2DM and Obesity

    Javier Morales, MD, FACP, FACE - Is Synergism the Secret to Success? Candid Conversations on Targeting GIP and GLP-1 to Individualize Treatment in Patients With T2DM and Obesity

    Go online to PeerView.com/KZF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have favorable, dose-dependent effects on both glycemia and weight, but dual incretin agonists may permit more intensive glycemic targets with greater weight loss. In this engaging PeerView Late Night activity, based on a recent live web broadcast, host Dr. Javier Morales is joined by special guests Drs. Juan Pablo Frías and Donna H. Ryan. Together, they discuss the interrelationship between type 2 diabetes mellitus (T2DM) and obesity, while exploring the potential role of combining glucose-dependent insulinotropic polypeptide (GIP) with GLP-1 RAs as dual incretin agonist therapy. GIP/GLP-1 RAs are evaluated in terms of their ability to personalize treatment for patients with T2DM and obesity, specifically for controlling glycemia and weight and avoiding long-term complications. Upon completion of this activity, participants should be better able to: Identify the individual role the incretin hormone GIP plays in healthy physiology and the synergistic role it has when combined with GLP-1, Differentiate the mechanism of action of dual GIP/GLP-1 RA therapy from GLP-1 RAs and its resulting effects on glycemic control, body weight, and lipid metabolism in patients with T2DM, Intensify therapy in a timely and patient-centered manner to optimize control of glycemia and weight consistent with the latest available evidence and avoid long-term complications in patients with T2DM and obesity.

    • 1 hr 5 min
    J. Fernando Arevalo - Seeing Eye to Eye: Improving Outcomes Among Rural Spanish-Speaking Latinx Patients With Diabetic Retinopathy or Diabetic Macular Edema

    J. Fernando Arevalo - Seeing Eye to Eye: Improving Outcomes Among Rural Spanish-Speaking Latinx Patients With Diabetic Retinopathy or Diabetic Macular Edema

    Go online to PeerView.com/DRR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in ophthalmology discusses improving vision outcomes among Spanish-speaking patients with DR and DME, including those residing in rural areas. Upon completion of this CE activity, participants will be able to: Describe the barriers that Spanish-speaking individuals, especially those living in rural areas, frequently encounter when seeking a diagnosis and/or treatment of DR/DME, Construct coordinated care plans with multidisciplinary providers (eg, PCPs, endocrinologists, ophthalmologists, retina specialists) to provide timely diagnosis and treatment for Spanish-speaking patients with DR/DME, especially those residing in rural areas, Discuss the efficacy and safety of anti-VEGF agents in a manner that acknowledges and overcomes patient barriers regarding their use, Implement communication strategies (eg, telehealth, patient education tools, translation services) to help reduce barriers to care and enhance healthcare delivery toward the goal of improving DR/DME outcomes in Spanish-speaking patients, especially those residing in rural areas.

    • 50 min
    John B. Buse, MD, PhD - Complementary Actions All Around: Lowering Cardiometabolic Risks While Achieving Glycemic Targets With GLP-1 RAs

    John B. Buse, MD, PhD - Complementary Actions All Around: Lowering Cardiometabolic Risks While Achieving Glycemic Targets With GLP-1 RAs

    Go online to PeerView.com/AZF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. How much do you really know about GLP-1 RAs in the management of T2DM? Test your knowledge about guideline recommendations, current evidence, and strategies to individualize treatment for patients with T2DM using GLP-1 RAs with realistic case-based scenarios. If you need a little help navigating a clinical scenario, a leading endocrinologist will examine current recommendations and evidence for GLP-1 RAs in the management of T2DM, as well as offer his insights on individualizing treatment plans to help patients reach their goals and reduce cardiovascular risks. Think you have all the answers? If so, you’ll be able to take the post-test and claim credit quickly! Upon completion of this CE activity, participants will be able to: Differentiate the therapeutic characteristics beyond glycemic control of GLP-1 RAs from other glucose-lowering agents, Construct individualized treatment regimens that uniquely target cardiometabolic and renal risk factors in patients with T2DM, Use shared decision-making with patients to discuss the ways GLP-1 RAs can be used safely and effectively to personalize treatment, improve adherence (eg, dosing frequency, route of administration), and reduce cardiometabolic risks.

    • 32 min
    Rohit Loomba, MD, MHSc - Test Your Knowledge of What’s Now and What’s Next: Modification of Metabolic Risk Factors to Improve Liver-Related and Cardiovascular‐Related Outcomes in NASH

    Rohit Loomba, MD, MHSc - Test Your Knowledge of What’s Now and What’s Next: Modification of Metabolic Risk Factors to Improve Liver-Related and Cardiovascular‐Related Outcomes in NASH

    Go online to PeerView.com/FCW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in hepatology provides practical guidance across the spectrum of care from screening and diagnosis to management of patients with nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). Upon completion of this activity, participants should be better able to: Discuss the epidemiology and disease burden of NAFLD/NASH, Describe the relationship between NAFLD/NASH and cardiovascular disease, Assess current and emerging treatments for NASH in the context of mechanism of action (eg, ability to target various metabolic, inflammatory, and fibrotic pathways involved in disease progression) and current clinical evidence (eg, impact on fibrosis and cardiovascular risk; safety)

    • 26 min

Customer Reviews

3.3 out of 5
4 Ratings

4 Ratings

Top Podcasts In Science

Hidden Brain
Alie Ward
Jordan Harbinger
Neil deGrasse Tyson
PRX and Greater Good Science Center
Sam Harris

You Might Also Like

JAMA Network
American Academy of Family Physicians
CardioNerds
Medscape
The New England Journal of Medicine
The Curbsiders Internal Medicine Podcast

More by PeerView Press

PVI, PeerView Institute for Medical Education
PVI, PeerView Institute for Medical Education
PVI, PeerView Institute for Medical Education
PVI, PeerView Institute for Medical Education
PVI, PeerView Institute for Medical Education
PVI, PeerView Institute for Medical Education